Abstract:<p>BACKGROUD & AIMS: Although SARS-CoV-2 infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection. We investigated changes in fecal microbiomes of patients with SARS-CoV-2 infection during hospitalization and associations with severity and fecal shedding of virus.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">METHODS</h3><p>We performed shotgun metagenomic sequencing analyses of fecal samples from 15 patients with COVID-19 in Hong Kong, from February 5 through March 17, 2020. Fecal samples were collected 2 or 3 times per week from time of hospitalization until discharge; disease was categorized as mild (no radiographic evidence of pneumonia), moderate (pneumonia was present), severe (respiratory rate ≥30/min, or oxygen saturation ≤93% when breathing ambient air), or critical (respiratory failure requiring mechanical ventilation, shock, or organ failure requiring intensive care). We compared microbiome data with those from 6 subjects with community-acquired pneumonia and 15 healthy individuals (controls). We assessed gut microbiome profiles in association with disease severity and changes in fecal shedding of SARS-CoV-2.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">RESULTS</h3><p>Patients with COVID-19 had significant alterations in fecal microbiomes compared with controls, characterized by enrichment of opportunistic pathogens and depletion of beneficial commensals, at time of hospitalization and at all timepoints during hospitalization. Depleted symbionts and gut dysbiosis persisted even after clearance of SARS-CoV-2 (determined from throat swabs) and resolution of respiratory symptoms. The baseline abundance of <em>Coprobacillus</em>, <em>Clostridium ramosum</em>, and <em>Clostridium hathewayi</em> correlated with COVID-19 severity; there was an inverse correlation between abundance of <em>Faecalibacterium prausnitzii</em> (an anti-inflammatory bacterium) and disease severity. Over the course of hospitalization, <em>Bacteroides dorei</em>, <em>Bacteroides thetaiotaomicron</em>, <em>Bacteroides massiliensis</em>, and <em>Bacteroides ovatus,</em> which downregulate expression of ACE2 in murine gut, correlated inversely with SARS-CoV-2 load in fecal samples from patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">CONCLUSIONS</h3><p>In a pilot study of 15 patients with COVID-19, we found persistent alterations in the fecal microbiome during the time of hospitalization, compared with controls. Fecal microbiota alterations were associated with fecal levels of SARS-CoV-2 and COVID-19 severity. Strategies to alter the intestinal microbiota might reduce disease severity.</p>

Gut microbiota from patients with COVID-19 cause alterations in mice that resemble post-COVID symptoms

Persistent intestinal dysbiosis after SARS-CoV-2 infection in Brazilian patients

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

Gut Microbiome Disruption Following SARS-CoV-2: A Review

Gut Microbiome and Cytokine Profiles in Post-COVID Syndrome

Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Gut Microbiome Alterations in COVID-19

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Dysbiosis of gut microbiota in patients with severe COVID-19

Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19

Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients

Alterations in Gut Microbiota Composition in Patients with COVID-19: A Pilot Study of Whole Hypervariable 16S rRNA Gene Sequencing

Gut microbiota composition in COVID-19 hospitalized patients with mild or severe symptoms

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia

Altered gut microbiome in convalescent patients with coronavirus disease 2019

Gut microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients

Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity